Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 18, No. 5, 2009
Issue release date: August 2009
Section title: Original Paper

Open Access Gateway

Med Princ Pract 2009;18:360–363

Does Imatinib Mesylate Therapy Cause Growth Hormone Deficiency?

Kebapcilar L.a · Bilgir O.b · Alacacioglu I.d · Payzin B.d · Bilgir F.c · Oner P.c · Sari I.c · Calan M.c · Binicier O.e
aDivision of Endocrinology and Metabolism, bDivision of Hematology and cDepartment of Internal Medicine, Bozyaka Training and Research Hospital, dDivision of Hematology, Department of Internal Medicine, Izmir Ataturk Training and Research Hospital,and eDepartment of Internal Medicine, Dokuz Eylul University, Izmir, Turkey
email Corresponding Author

Levent Kebapcilar

Division of Endocrinology and Metabolism

Department of Internal Medicine, Bozyaka Training and Research Hospital

123/4 Street No: 10 A flat: 4, TR–35340 Izmir (Turkey)

Tel. +90 50 5448 2857, Fax +90 238 4038, E-Mail leventkebapcilar@yahoo.com

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Objective: The purpose of this study was to determinewhether or not imatinib mesylate therapy induces growth hormone deficiency (GHD). Subjects and Methods: Seventeen patients with chronic myloid leukemia (CML) were enrolled in the study. The glucagon stimulation test (GST), and standard deviation scores (SDSs) of insulin-like growth fac- tor 1 (IGF-I) and insulin-like growth factor binding protein (IGFBP-3) were used to determine GHD. The L-dopa test was performed on those with IGF-I SDSs above the –1.8 cut-off level. Results: Of the 17 patients in the study, 12 (70%) had severe GHD (serum GH level <3 μg/l after GST). IGF-I SDSs and IGFBP-3 SDSs were below –1.8 in 12 patients (70%) and below –0.9 in 10 subjects (58%). Four of the 5 remaining subjects with IGF-I SDS >–1.8 showed insufficient GH response to L-dopa stimulation. Nine subjects (52%) had both severe GHD based on GST response and IGF-I SDS below –1.8. If an IGF-I SDS cut-off value l<–3 were used,5 out of 17 subjects (30%) would be classified as GH deficient. These same patients also showed severe GHD based on GST response. Conclusions: The data showed that a large number of patients on imatinib mesylate therapy had GH deficiency. A study involving a larger number of patients with a matched control group is needed to confirm the present observations.

© 2009 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: October 12, 2008
Accepted: November 23, 2008
Published online: July 31, 2009
Issue release date: August 2009

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 1

ISSN: 1011-7571 (Print)
eISSN: 1423-0151 (Online)

For additional information: http://www.karger.com/MPP

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.